Stem Cells in Fertility: Research Status and Limits

Key Takeaways

Stem cells are being studied as a regenerative approach for some infertility problems, especially ovarian injury, premature ovarian insufficiency, and selected uterine conditions. The science is scientifically interesting, but most stem-cell use in fertility is still experimental and should not be confused with proven fertility treatment.

Key evidence: Mesenchymal Stem Cells to Treat Female Infertility: Review · ASRM: Fertility Evaluation of Infertile Women (2021)

On this page

• Stem Cells in Fertility Care
• What Researchers Mean by Stem-Cell Treatment
• Clinical Questions Still Unanswered
• Main Clinical Limitations
• What Patients Should Ask
• Conclusion

Stem Cells in Fertility Care

Stem cell research represents an evolving area of regenerative medicine in reproductive biology (MSC Infertility Review).

While biological interest is high, stem-cell fertility therapies remain experimental and are not approved for routine clinical use.

What Researchers Mean by Stem-Cell Treatment

Most reproductive studies focus on mesenchymal stem cells (MSCs) derived from bone marrow, adipose tissue, or umbilical cord blood.

Target research areas:

• Premature Ovarian Insufficiency (POI): Evaluating stromal cell signaling to restore follicular activity.
• Ovarian Injury: Assessing repair after chemotherapy or pelvic radiotherapy.
• Refractory Thin Endometrium: Investigating endometrial tissue regeneration.
• Severe Intrauterine Adhesions: Exploring Asherman syndrome scar modification.

Clinical Questions Still Unanswered

Before any experimental therapy can be accepted as clinical care, key scientific questions must be answered:

• Follicular Response: Does it reliably stimulate mature oocyte development?
• Embryo Yield: Does it increase usable blastocyst rates?
• Live Birth Rate: Does it demonstrate statistically significant live birth improvement in human RCTs?
• Long-Term Safety: What are the immunological and epigenetic impacts on offspring?

Main Clinical Limitations

• Inconsistent cell isolation, expansion, and preparation protocols.
• Absence of standardized administration routes (e.g., intra-ovarian injection vs. systemic infusion).
• Limited human clinical trial data with randomized control groups.
• Variable regulatory oversight across different countries.

What Patients Should Ask

If offered stem-cell treatment at a commercial clinic, patients should inquire:

• Is the procedure part of an IRB-approved clinical trial?
• Are live birth rates published in peer-reviewed journals?
• How does the protocol compare to evidence-based IVF or donor egg options?

Conclusion

Stem-cell therapies hold scientific potential for severe ovarian and uterine pathology, but remain strictly experimental until robust clinical trial data confirm efficacy and safety.

Sources

• Mesenchymal Stem Cells to Treat Female Infertility; Future Perspective and Challenges: A Review
• Mesenchymal Stem Cells Promote Ovarian Reconstruction in Mice
• ASRM: Fertility Evaluation of Infertile Women (2021)

Dr. Senai Aksoy

Dr. Senai Aksoy studied and trained in France before returning to Turkey, where he was a founding member of the ICSI team at Sevgi Hospital, Ankara — the country's first ICSI centre (1994-95) — and a co-author on the first Turkish ICSI publications produced in collaboration with the Brussels Van Steirteghem group (Human Reproduction, 1996; PMID 8671323). He helped build the IVF programme at the American Hospital Istanbul and has been running his own fertility practice since 1998.

Verified profiles: PubMed · ORCID · LinkedIn

Read full profile → Instagram YouTube

The content has been created by Dr. Senai Aksoy and medically approved.